A biotech stock just rocketed 608% after announcing positive phase 3 trial data (MCRB)
· *Seres Therapeutics soared as much as 608% on Monday after the company announced positive phase 3 trial data for its drug SER-109.*
· *SER-109 was developed for the potential treatment of C. difficile, which is a bacterial infection of the colon that leads to inflammation and can be deadly.*
· *Seres said that SER-109 was...